Anti-Spike Antibodies Among Vaccinated Predict Major Adverse Events after Myocardial Infarction

Broadcast Message

COVID-19 era highlights importance of total quantitative antibodies against Spike protein, reflecting SARS-CoV-2 exposure. Blasco et al found vaccinated individuals showed higher antibody levels linked to major adverse cardiac events (MACE) post-vaccination, averaging 142 days to heart attack. Study lacks details on COVID-19 infection timing and vaccine exposure effects. Spike antibody levels may indicate prognosis; further research on Spike protein's role in vascular damage is needed.

Link

https://petermcculloughmd.substack.com/p/anti-spike-antibodies-among-vaccinated

Anti-Spike Antibodies Among Vaccinated Predict Major Adverse Events after Myocardial Infarction Lab Test Indirectly Implicates Spike as Cause of Complications after Heart Attack Thu, 19 Sep 2024 09:43:55 GMT https://petermcculloughmd.substack.com/p/anti-spike-antibodies-among-vaccinated By Peter A. McCullough, MD, MPH

The medical community is learning one of the most valuable tests in the COVID-19 era is the total quantitative antibodies against the Spike protein. This test reflects exposure to the Spike protein from SARS-CoV-2 infection and also COVID-19 vaccination particularly with mRNA and adenoviral DNA vaccines.

Blasco et al reported on heart attacks occurring from March, 2020 to March, 2023. The unvaccinated must have come from 2020 before the advent of COVID-19 vaccines on the Spanish market. Antibodies were much higher in those who took one or more COVID-19 vaccines and they were associated with major adverse cardiac events (MACE) such as recurrent infarction and cardiac death. The time from vaccination to heart attack was 142 days on average. Of note, only the vaccinated with elevated anti-Spike levels were independently associated with this outcome.

Blasco A, Royuela A, García-Gómez S, Gómez-Lozano N, Sánchez-Arjona A, de la Fuente J, Anel J, Sánchez-Galarraga I, Pérez-Redondo M, González E, Silva L. Association of SARS-CoV-2 immunoserology and vaccination status with myocardial infarction severity and outcome. Vaccine. 2024 Sep 7;42(26):126305. doi: 10.1016/j.vaccine.2024.126305. Epub ahead of print. PMID: 39244425.

The shortcomings of this paper are detailed information on when the subjects contracted COVID-19, how many times, and the combined exposure of vaccination after previous infection and COVID-19 illness upon vaccine failure. Nevertheless, the Spike antibody level appeared to be prognostic.

Hopefully the academic community will do more work with this important marker of infection and COVID-19 vaccine exposure and soon move to directly measuring Spike protein itself as a pathogenic factor proven to cause blood vessel damage, myopericarditis, and thrombosis.

Courageous Discourse™ with Dr. Peter McCullough & John Leake is a reader-supported publication. To receive new posts and support my work, consider becoming a free or paid subscriber.

Please subscribe to Courageous Discourse as a paying ($5 monthly) or founder member so we can continue to bring you the truth.

Peter A. McCullough, MD, MPH

President, McCullough Foundation